GONGWIN BIOPHARM HOLDINGS CO., LTD. Financials Gongwin Biopharm Holdings Co., Ltd.
Equities
6617
KYG409471060
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 181 TWD | -0.28% |
|
-0.28% | -1.90% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 6,865 | 8,244 | 26,551 | 31,104 | 36,132 | 20,911 |
| Enterprise Value (EV) 1 | 6,211 | 7,622 | 25,549 | 30,393 | 35,168 | 20,045 |
| P/E ratio | -60.9 x | -75.1 x | -273 x | -255 x | -140 x | -207 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 110,731 x | 33,242 x | 31,874 x | 27,213 x | 31,611 x | 1,105 x |
| EV / Revenue | 100,179 x | 30,732 x | 30,671 x | 26,590 x | 30,768 x | 1,060 x |
| EV / EBITDA | -52.9 x | -61.9 x | -231 x | -269 x | -139 x | -160 x |
| EV / FCF | -41.2 x | -213 x | -270 x | -127 x | -138 x | -855 x |
| FCF Yield | -2.42% | -0.47% | -0.37% | -0.79% | -0.73% | -0.12% |
| Price to Book | 8.93 x | 12.4 x | 24.3 x | 32 x | 26 x | 15.9 x |
| Nbr of stocks (in thousands) | 102,774 | 103,063 | 109,265 | 109,908 | 113,088 | 113,336 |
| Reference price 2 | 66.80 | 79.99 | 243.0 | 283.0 | 319.5 | 184.5 |
| Announcement Date | 4/29/19 | 4/17/20 | 4/14/21 | 4/14/22 | 4/24/23 | 4/12/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.062 | 0.248 | 0.833 | 1.143 | 1.143 | 18.92 |
| EBITDA 1 | -117.5 | -123.2 | -110.6 | -112.8 | -252.2 | -125 |
| EBIT 1 | -123.8 | -128.8 | -117.4 | -120.8 | -260.7 | -133.3 |
| Operating Margin | -199,758.06% | -51,944.76% | -14,089.56% | -10,570.95% | -22,806.74% | -704.87% |
| Earnings before Tax (EBT) 1 | -114 | -115.3 | -99.32 | -114.7 | -292.1 | -101.2 |
| Net income 1 | -110.7 | -109.8 | -93.07 | -121.6 | -254.2 | -101.2 |
| Net margin | -178,624.19% | -44,283.87% | -11,173.11% | -10,637.01% | -22,238.76% | -534.89% |
| EPS 2 | -1.097 | -1.066 | -0.8909 | -1.110 | -2.287 | -0.8932 |
| Free Cash Flow 1 | -150.6 | -35.78 | -94.65 | -239.9 | -255.3 | -23.45 |
| FCF margin | -242,874.8% | -14,428.58% | -11,362.21% | -20,992.98% | -22,332.13% | -124% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/29/19 | 4/17/20 | 4/14/21 | 4/14/22 | 4/24/23 | 4/12/24 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 654 | 622 | 1,003 | 711 | 964 | 865 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -151 | -35.8 | -94.6 | -240 | -255 | -23.5 |
| ROE (net income / shareholders' equity) | -17% | -15.6% | -10.9% | -12.3% | -24.7% | -7.54% |
| ROA (Net income/ Total Assets) | -9.75% | -9.43% | -7.41% | -6.36% | -11.7% | -5.31% |
| Assets 1 | 1,136 | 1,165 | 1,255 | 1,913 | 2,179 | 1,905 |
| Book Value Per Share 2 | 7.480 | 6.460 | 10.00 | 8.830 | 12.30 | 11.60 |
| Cash Flow per Share 2 | 1.670 | 1.840 | 6.470 | 4.130 | 5.940 | 2.410 |
| Capex 1 | 59.3 | 8.32 | 30.1 | 123 | 7.34 | 0.91 |
| Capex / Sales | 95,611.29% | 3,356.45% | 3,617.77% | 10,762.2% | 641.91% | 4.79% |
| Announcement Date | 4/29/19 | 4/17/20 | 4/14/21 | 4/14/22 | 4/24/23 | 4/12/24 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -1.90% | 636M | |
| +10.44% | 106B | |
| +0.82% | 104B | |
| +6.72% | 23.25B | |
| -13.89% | 22.5B | |
| -6.64% | 18.7B | |
| -37.26% | 17.95B | |
| -10.98% | 16.99B | |
| +8.67% | 14.26B | |
| +41.08% | 12.76B |
- Stock Market
- Equities
- 6617 Stock
- Financials Gongwin Biopharm Holdings Co., Ltd.